{
    "root": "37328161-b71b-4ed2-9708-baaf19693bc2",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Phentermine hydrochloride",
    "value": "20250131",
    "ingredients": [
        {
            "name": "PHENTERMINE HYDROCHLORIDE",
            "code": "0K2I505OTV",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_50506"
        },
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_17716"
        },
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_30563"
        },
        {
            "name": "STARCH, CORN",
            "code": "O8232NY3SJ",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_28017"
        },
        {
            "name": "FD&C BLUE NO. 1",
            "code": "H3R47K3TBD"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14077"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14158"
        },
        {
            "name": "SUCROSE",
            "code": "C151H8M554",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_17992"
        },
        {
            "name": "STEARIC ACID",
            "code": "4ELV7Z65AP",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_37527"
        }
    ],
    "indications": {
        "text": "phentermine hydrochloride indicated short-term ( weeks ) adjunct regimen weight reduction based exercise , behavioral modification caloric restriction management exogenous obesity patients initial body mass index \u2265 30 kg/m2 , \u2265 27 kg/m2 presence risk factors ( e.g . , controlled hypertension , diabetes , hyperlipidemia ) . chart body mass index ( bmi ) based various heights weights . bmi calculated taking patient \u2019 weight , kilograms ( kg ) , divided patient \u2019 height , meters ( ) , squared . metric conversions follows : pounds \u00f7 2.2 = kg ; inches x 0.0254 = meters . limited usefulness agents class , including phentermine , [ pharmacology ( 12.1 , 12.2 ) ] measured possible risk factors inherent described .",
        "doid_entities": [
            {
                "text": "obesity (DOID:9970)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_9970"
            },
            {
                "text": "hypertension (DOID:10763)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_10763"
            },
            {
                "text": "diabetes (DOID:9351)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_9351"
            }
        ],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": "individualized obtain adequate response lowest effective dose . ( 2.1 ) late evening avoided ( risk insomnia ) . ( 2.1 ) phentermine hydrochloride taken without food . ( 2.1 ) limit 15 mg daily patients severe renal impairment ( egfr 15 29 ml/min/1.73m 2 ) - ( 2.2 )",
        "doid_entities": [],
        "orphanet_entities": [
            {
                "disease": "severe renal impairment",
                "orphanet_id": "http://www.orpha.net/ORDO/Orphanet_447788"
            }
        ]
    },
    "warningsAndPrecautions": "available tablets containing 37.5 mg phentermine hydrochloride ( equivalent 30 mg phentermine base ) . white blue specks , capsule shaped tablet debossed \u201c n \u201d left side bisect \u201c 4 \u201d right side bisect one side plain side , functional score . tablets packaged bottles 1000 ( ndc 71335-2297-1 ) 100 ( ndc 71335-2297-2 ) store 20\u00b0 25\u00b0c ( 68\u00b0 77\u00b0f ) [ usp controlled room temperature ] . dispense tight container defined usp , child-resistant closure ( required ) . keep medications reach children . repackaged/relabeled : bryant ranch prepack , inc.burbank , ca 91504",
    "adverseReactions": "\u2022 history cardiovascular disease ( e.g . , coronary artery disease , stroke , arrhythmias , congestive heart failure , uncontrolled hypertension ) \u2022 within 14 days following monoamine oxidase inhibitors\u2022 hyperthyroidism\u2022 glaucoma\u2022 agitated states\u2022 history abuse\u2022 pregnancy [ ( 8.1 ) ] \u2022 nursing [ ( 8.3 ) ] \u2022 known hypersensitivity , idiosyncrasy sympathomimetic amines",
    "indications_original": "Phentermine hydrochloride is indicated as a short-term (a few weeks) adjunct in a regimen of weight reduction based on exercise, behavioral modification and caloric restriction in the management of exogenous obesity for patients with an initial body mass index \u2265 30 kg/m2, or \u2265 27 kg/m2 in the presence of other risk factors (e.g., controlled hypertension, diabetes, hyperlipidemia).\n                  Below is a chart of body mass index (BMI) based on various heights and weights.\n                  BMI is calculated by taking the patient\u2019s weight, in kilograms (kg), divided by the patient\u2019s height, in meters (m), squared. Metric conversions are as follows: pounds \u00f7 2.2 = kg; inches x 0.0254 = meters.\n                  \n                     \n                        \n                     \n                  \n                  The limited usefulness of agents of this class, including phentermine, [see Clinical Pharmacology (\n                     \n                        12.1\n                     \n                     , \n                     \n                        12.2\n                     \n                     )] should be measured against possible risk factors inherent in their use such as those described below.",
    "contraindications_original": "Dosage should be individualized to obtain an adequate response with the lowest effective dose. (2.1) Late evening administration should be avoided (risk of insomnia). (2.1) Phentermine hydrochloride\u00a0can be taken with or without food. (2.1) Limit the dosage to 15 mg daily for patients with severe renal impairment (eGFR 15 to 29 mL/min/1.73m 2 )- ( 2.2 )",
    "warningsAndPrecautions_original": "Available in tablets containing 37.5 mg phentermine hydrochloride (equivalent to 30 mg phentermine base). Each white with blue specks, capsule shaped tablet is debossed with \u201cN\u201d on the left side of bisect and \u201c4\u201d on the right side of bisect on one side and plain on the other side, having a functional score.\n                  Tablets are packaged in bottles of 1000 (NDC 71335-2297-1) and 100 (NDC 71335-2297-2)\n                  Store at 20\u00b0 to 25\u00b0C (68\u00b0 to 77\u00b0F) [See USP Controlled Room Temperature].\n                  Dispense in a tight container as defined in the USP, with a child-resistant closure (as required).\n                  KEEP THIS AND ALL MEDICATIONS OUT OF THE REACH OF THE CHILDREN.\n                  Repackaged/Relabeled by:Bryant Ranch Prepack, Inc.Burbank, CA 91504",
    "adverseReactions_original": "\u2022 History of cardiovascular disease (e.g., coronary artery disease, stroke, arrhythmias, congestive heart failure, uncontrolled hypertension)\u2022 During or within 14 days following the administration of monoamine oxidase inhibitors\u2022 Hyperthyroidism\u2022 Glaucoma\u2022 Agitated states\u2022 History of drug abuse\u2022 Pregnancy [see Use in Specific Populations (\n                     \n                        8.1\n                     \n                     )]\u2022 Nursing [see Use in Specific Populations (\n                     \n                        8.3\n                     \n                     )]\u2022 Known hypersensitivity, or idiosyncrasy to the sympathomimetic amines",
    "drug": [
        {
            "name": "Phentermine hydrochloride",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_50506"
        }
    ]
}